FI62282C - Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror Download PDFInfo
- Publication number
- FI62282C FI62282C FI753613A FI753613A FI62282C FI 62282 C FI62282 C FI 62282C FI 753613 A FI753613 A FI 753613A FI 753613 A FI753613 A FI 753613A FI 62282 C FI62282 C FI 62282C
- Authority
- FI
- Finland
- Prior art keywords
- acid
- aminomethyl
- compound
- formula
- solution
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 12
- -1 cyclic amino acids Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000006969 Curtius rearrangement reaction Methods 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000006462 rearrangement reaction Methods 0.000 claims description 2
- 238000006644 Lossen rearrangement reaction Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 5
- MXNASYICBPHSLF-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCCCC1 MXNASYICBPHSLF-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VZQSZPCSJJSCDJ-UHFFFAOYSA-N 1-(azaniumylmethyl)cyclopentane-1-carboxylate Chemical compound NCC1(C(O)=O)CCCC1 VZQSZPCSJJSCDJ-UHFFFAOYSA-N 0.000 description 3
- SAYBRQDMVZLOPM-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylsulfanyl]acetic acid Chemical compound OC(=O)CSCC1=CC=C(Cl)C=C1 SAYBRQDMVZLOPM-UHFFFAOYSA-N 0.000 description 3
- VLFQWYHVTAGEQB-UHFFFAOYSA-N 2-[1-(2-methoxy-2-oxoethyl)cyclohexyl]acetic acid Chemical compound COC(=O)CC1(CC(O)=O)CCCCC1 VLFQWYHVTAGEQB-UHFFFAOYSA-N 0.000 description 3
- XBUDZAQEMFGLEU-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]acetic acid;hydron;chloride Chemical compound Cl.OC(=O)CC1(CN)CCCCC1 XBUDZAQEMFGLEU-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- RQZKNSBTUBWVJG-UHFFFAOYSA-N 1-(aminomethyl)cyclopentane-1-carboxylic acid;hydrochloride Chemical compound Cl.NCC1(C(O)=O)CCCC1 RQZKNSBTUBWVJG-UHFFFAOYSA-N 0.000 description 2
- CQAHQVNBEBOLQB-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]acetic acid;hydrochloride Chemical compound Cl.OC(=O)CC1(CN)CCCCCC1 CQAHQVNBEBOLQB-UHFFFAOYSA-N 0.000 description 2
- XFLACBVNBXGJKW-UHFFFAOYSA-N 2-[1-(carboxymethyl)cycloheptyl]acetic acid Chemical compound OC(=O)CC1(CC(O)=O)CCCCCC1 XFLACBVNBXGJKW-UHFFFAOYSA-N 0.000 description 2
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 2
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 2
- GFWLMILMVMCJDI-UHFFFAOYSA-N 8-oxaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)OC(=O)CC11CCCC1 GFWLMILMVMCJDI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- PQCNPWAMVMHDID-UHFFFAOYSA-N ethyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound CCOC(=O)CC1(CN)CCCCC1 PQCNPWAMVMHDID-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- SYKKFHNKTXXXCK-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound COC(=O)CC1(CN)CCCCC1 SYKKFHNKTXXXCK-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- MXOVZDDZXRYXLR-UHFFFAOYSA-M 2-[1-(2-methoxy-2-oxoethyl)cycloheptyl]acetate Chemical compound COC(=O)CC1(CC([O-])=O)CCCCCC1 MXOVZDDZXRYXLR-UHFFFAOYSA-M 0.000 description 1
- IFXLHDQDEBMQIT-UHFFFAOYSA-N 2-[1-(2-methoxy-2-oxoethyl)cycloheptyl]acetic acid;azide Chemical compound [N-]=[N+]=[N-].COC(=O)CC1(CC(O)=O)CCCCCC1 IFXLHDQDEBMQIT-UHFFFAOYSA-N 0.000 description 1
- WMRCVFGWAKNFMD-UHFFFAOYSA-N 2-[1-(2-methoxy-2-oxoethyl)cyclopentyl]acetic acid Chemical compound COC(=O)CC1(CC(O)=O)CCCC1 WMRCVFGWAKNFMD-UHFFFAOYSA-N 0.000 description 1
- XNDSIASQMRYFSW-UHFFFAOYSA-N 3-oxaspiro[5.5]undecane-2,4-dione Chemical compound C1C(=O)OC(=O)CC11CCCCC1 XNDSIASQMRYFSW-UHFFFAOYSA-N 0.000 description 1
- CGSIJCLRVFEHNY-UHFFFAOYSA-N 3-oxaspiro[5.6]dodecane-2,4-dione Chemical compound C1C(=O)OC(=O)CC21CCCCCC2 CGSIJCLRVFEHNY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DTKQLNITIDDCIG-UHFFFAOYSA-N C1(=CC=CC=C1)S(=O)(=O)O.NO Chemical compound C1(=CC=CC=C1)S(=O)(=O)O.NO DTKQLNITIDDCIG-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JMLSMHLKFFZZLT-UHFFFAOYSA-N NCC1(CCCCCC1)CC(=O)O.NCC1(CCCCCC1)CC(=O)O Chemical compound NCC1(CCCCCC1)CC(=O)O.NCC1(CCCCCC1)CC(=O)O JMLSMHLKFFZZLT-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- CVBYVUQVPQRITK-UHFFFAOYSA-N acetic acid;benzenesulfonic acid Chemical compound CC(O)=O.OS(=O)(=O)C1=CC=CC=C1 CVBYVUQVPQRITK-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KEXDWNYDFPGSCM-UVUXOWFKSA-N butyl (6r)-6-methylpiperidine-2-carboxylate;hydrochloride Chemical compound Cl.CCCCOC(=O)C1CCC[C@@H](C)N1 KEXDWNYDFPGSCM-UVUXOWFKSA-N 0.000 description 1
- VSPRNAOBIBJEAJ-UHFFFAOYSA-N butyl 2-[1-(aminomethyl)cyclopentyl]acetate;hydrochloride Chemical compound Cl.CCCCOC(=O)CC1(CN)CCCC1 VSPRNAOBIBJEAJ-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- DGEYTDCFMQMLTH-UHFFFAOYSA-N methanol;propan-2-ol Chemical compound OC.CC(C)O DGEYTDCFMQMLTH-UHFFFAOYSA-N 0.000 description 1
- BPUUTTKHBSNDRT-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cycloheptyl]acetate Chemical compound COC(=O)CC1(CN)CCCCCC1 BPUUTTKHBSNDRT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- PVEFEIWVJKUCLJ-UHFFFAOYSA-N sulfuric acid;toluene Chemical compound OS(O)(=O)=O.CC1=CC=CC=C1 PVEFEIWVJKUCLJ-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2460891 | 1974-12-21 | ||
| DE2460891A DE2460891C2 (de) | 1974-12-21 | 1974-12-21 | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI753613A7 FI753613A7 (OSRAM) | 1976-06-22 |
| FI62282B FI62282B (fi) | 1982-08-31 |
| FI62282C true FI62282C (fi) | 1982-12-10 |
Family
ID=5934284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI753613A FI62282C (fi) | 1974-12-21 | 1975-12-19 | Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4024175A (OSRAM) |
| JP (1) | JPS5324064B2 (OSRAM) |
| AT (1) | AT340892B (OSRAM) |
| BE (1) | BE836835A (OSRAM) |
| CA (1) | CA1052811A (OSRAM) |
| CH (3) | CH612665A5 (OSRAM) |
| DE (1) | DE2460891C2 (OSRAM) |
| DK (1) | DK147706C (OSRAM) |
| ES (1) | ES443723A1 (OSRAM) |
| FI (1) | FI62282C (OSRAM) |
| FR (1) | FR2294697A1 (OSRAM) |
| GB (1) | GB1465229A (OSRAM) |
| IE (1) | IE42382B1 (OSRAM) |
| LU (1) | LU74058A1 (OSRAM) |
| NL (1) | NL181006C (OSRAM) |
| SE (1) | SE423385B (OSRAM) |
Families Citing this family (221)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2611690A1 (de) * | 1976-03-19 | 1977-09-22 | Goedecke Ag | Cyclische sulfonyloxyimide |
| JPS5776189U (OSRAM) * | 1980-10-28 | 1982-05-11 | ||
| JPS6152583U (OSRAM) * | 1984-09-11 | 1986-04-09 | ||
| JPS61139881U (OSRAM) * | 1985-02-21 | 1986-08-29 | ||
| US4876279A (en) * | 1986-05-05 | 1989-10-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4960931A (en) * | 1988-05-02 | 1990-10-02 | Warner-Lambert Company | Gabapentin mohohydrate and a process for producing the same |
| US4894476A (en) * | 1988-05-02 | 1990-01-16 | Warner-Lambert Company | Gabapentin monohydrate and a process for producing the same |
| YU162789A (en) * | 1988-09-01 | 1990-12-31 | Lonza Ag | 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones |
| US5132451A (en) * | 1989-08-25 | 1992-07-21 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
| US5319135A (en) * | 1989-08-25 | 1994-06-07 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
| DE3928183A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| DE3928182A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von gabapentin |
| DE3928184A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte |
| PH27359A (en) * | 1989-08-25 | 1993-06-21 | Warner Lambert Co | Process for cyclic amino acid anticonvulsant compounds |
| US5260467A (en) * | 1989-11-16 | 1993-11-09 | Pfizer Inc. | Glutaric acid derivatives and preparation thereof |
| FI905584L (fi) * | 1989-11-16 | 1991-05-17 | Lonza Ag | Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra. |
| US5136091A (en) * | 1989-11-16 | 1992-08-04 | Lonza Ltd. | Process for the production of 1-(aminomethyl) cyclohexane acetic acid |
| US5157138A (en) * | 1989-11-16 | 1992-10-20 | Pfizer, Inc. | Glutaric acid derivatives and preparation thereof |
| GB8925933D0 (en) * | 1989-11-16 | 1990-01-04 | Pfizer Ltd | Glutaric acid derivatives and preparation thereof |
| US5149870A (en) * | 1989-11-16 | 1992-09-22 | Lonza Ltd. | Process for the production of 1-(aminomethyl)cyclohexane acetic acid |
| US5084479A (en) * | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5025035A (en) * | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
| US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| ES2176668T3 (es) * | 1996-02-07 | 2002-12-01 | Warner Lambert Co | Aminoacidos ciclicos novedosos como agentes farmaceuticos. |
| JP2000506861A (ja) * | 1996-03-14 | 2000-06-06 | ワーナー―ランバート・コンパニー | 医薬としての新規な置換環状アミノ酸 |
| EP0888285B1 (en) * | 1996-03-14 | 2001-12-12 | Warner-Lambert Company | Novel bridged cyclic amino acids as pharmaceutical agents |
| AU714980B2 (en) | 1996-07-24 | 2000-01-13 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
| CA2263663C (en) * | 1996-10-23 | 2006-05-30 | Justin Stephen Bryans | Substituted gamma aminobutyric acids as pharmaceutical agents |
| IL119890A (en) * | 1996-12-24 | 2002-03-10 | Teva Pharma | Gabapentin form iii and preparation of gabapentin form ii |
| US6255526B1 (en) | 1996-12-24 | 2001-07-03 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| WO1999008667A2 (en) | 1997-08-19 | 1999-02-25 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
| DK1011658T3 (da) * | 1997-09-08 | 2006-04-03 | Warner Lambert Co | Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme |
| US6294690B1 (en) | 1997-10-07 | 2001-09-25 | Warner-Lambert Company | Process for preparing a cyclic amino acid anticonvulsant compound |
| HUP0004310A3 (en) * | 1997-10-27 | 2001-11-28 | Warner Lambert Co | Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents |
| US6984659B2 (en) * | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
| JP2002508361A (ja) | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用 |
| AU759392B2 (en) | 1997-12-16 | 2003-04-10 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| DE69826151T2 (de) | 1997-12-16 | 2005-01-27 | Warner-Lambert Co. Llc | 1-substituierte-1-aminomethyl-cycloalkan derivate (= gabapentin analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen |
| WO1999037296A1 (en) * | 1998-01-23 | 1999-07-29 | Warner-Lambert Company | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| IL139298A0 (en) | 1998-05-15 | 2001-11-25 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| BR9910494B1 (pt) * | 1998-05-15 | 2011-11-01 | composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo. | |
| ES2137137B1 (es) * | 1998-05-25 | 2000-08-16 | Medichem Sa | Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. |
| JP2002516312A (ja) | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物 |
| ITMI981535A1 (it) * | 1998-07-03 | 2000-01-03 | Zambon Spa | Processo per la preparazione di gabapentina |
| US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| FR2781793B1 (fr) | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| HU225502B1 (en) * | 1998-12-29 | 2007-01-29 | Richter Gedeon Vegyeszet | Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates |
| IT1311984B1 (it) | 1999-03-26 | 2002-03-22 | Bioindustria Lab Italiano Medi | Procedimento per la preparzione di gabapentin. |
| AU4334900A (en) * | 1999-04-09 | 2000-11-14 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
| US6710190B1 (en) | 1999-05-28 | 2004-03-23 | Warner-Lambert Company | 3-heteroarylalkyl substituted gaba analogs |
| PT1185524E (pt) * | 1999-05-28 | 2005-04-29 | Warner Lambert Co | Analogos de gaba substituidos por 3-heteroarilalquilo |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| IL146969A0 (en) * | 1999-06-10 | 2002-08-14 | Warner Lambert Co | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| US6294198B1 (en) | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
| HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| DE60101476T2 (de) | 2000-06-16 | 2004-05-27 | Teva Pharmaceutical Industries Ltd. | Stabiles gabapentin, das mehr als 20 ppm chlor enthält |
| EP1384473A1 (en) * | 2000-06-16 | 2004-01-28 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chlorine ion |
| NZ523546A (en) * | 2000-06-16 | 2005-04-29 | Teva Pharma | Stable pharmaceutical compositions of gabapentin having PH within the range 6.8 to 7.3 comprising less than 0.5% by weight of a corresponding lactum |
| PT1296671E (pt) * | 2000-06-26 | 2008-05-09 | Warner Lambert Co | Substâncias análogas à gabapentina para o tratamento de perturbações do sono |
| GB2364049A (en) * | 2000-06-28 | 2002-01-16 | Warner Lambert Co | Cyclic ketones and their use in the synthesis of amino acids |
| EP1317426B1 (de) * | 2000-09-14 | 2005-11-16 | Grünenthal GmbH | Beta-thio-aminosäuren |
| EP1361847A2 (en) * | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| AU2002211863A1 (en) * | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| IT1319234B1 (it) * | 2000-10-23 | 2003-09-26 | Zambon Spa | Processo di preparazione di gabapentina. |
| GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| CN1471507A (zh) * | 2000-11-02 | 2004-01-28 | ������ҩ��ҵ����˾ | 用于制备加巴喷丁中间体的改进方法 |
| CA2430298A1 (en) * | 2000-11-30 | 2002-06-06 | Banavara Lakshman Mylari | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| AP2001002359A0 (en) * | 2000-11-30 | 2001-12-31 | Pfizer Prod Inc | Combination of gaba agonists and aldose reductase inhibitors. |
| IT1319674B1 (it) * | 2000-12-01 | 2003-10-23 | Erregierre Spa | Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico. |
| WO2002074727A1 (en) * | 2001-03-16 | 2002-09-26 | Solchem Italiana S.P.A. | A process for the preparation of cyclic amino acids |
| ITMI20011132A1 (it) | 2001-05-29 | 2002-11-29 | Procos Spa | Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico |
| US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ES2296956T5 (es) * | 2001-06-11 | 2011-07-12 | Xenoport, Inc. | Profármacos de análogos de gaba, composiciones y sus usos. |
| EP1412324A4 (en) * | 2001-06-11 | 2004-09-29 | Xenoport Inc | AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| IL144066A0 (en) * | 2001-06-28 | 2002-04-21 | Bromine Compounds Ltd | Process for the preparation of 1,1-cyclohexane diacetic monoamide |
| ITMI20011772A1 (it) | 2001-08-10 | 2003-02-10 | A M S A Anonima Materie Sint E | Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide) |
| EP1423168B1 (en) | 2001-09-03 | 2006-02-08 | Newron Pharmaceuticals S.p.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
| US6800782B2 (en) * | 2001-10-09 | 2004-10-05 | Warner-Lambert Co. | Anhydrous crystalline forms of gabapentin |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20030119908A1 (en) * | 2001-12-21 | 2003-06-26 | Zambon Group S.P.A. | Stable gabapentin compositions |
| ITMI20012750A1 (it) | 2001-12-21 | 2003-06-21 | Procos Spa | Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura |
| PL371944A1 (en) * | 2002-01-31 | 2005-07-11 | Warner-Lambert Company Llc | Alpha 2 delta ligands to treat tinnitus |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| WO2003080588A1 (en) | 2002-03-20 | 2003-10-02 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
| WO2003089403A1 (en) * | 2002-04-16 | 2003-10-30 | Taro Pharmaceutical Industries Ltd. | Process for preparing gabapentin |
| WO2003094842A2 (en) * | 2002-05-07 | 2003-11-20 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
| US7183259B2 (en) * | 2002-05-17 | 2007-02-27 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| WO2004002462A2 (en) * | 2002-06-27 | 2004-01-08 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| CA2395931A1 (en) * | 2002-08-07 | 2004-02-07 | Bernard Charles Sherman | Solid compositions comprising gabapentin having improved stability |
| US7053122B2 (en) * | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US20040092591A1 (en) * | 2002-08-15 | 2004-05-13 | Blakemore David Clive | Therapeutic use of fused bicyclic or tricyclic amino acids |
| US20040092498A1 (en) * | 2002-08-16 | 2004-05-13 | David Blakemore | Substituted glycine derivatives for use as medicaments |
| ITMI20022071A1 (it) * | 2002-10-01 | 2004-04-02 | Erregierre Spa | Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato. |
| US7659305B2 (en) * | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| CA2472815A1 (en) * | 2002-11-18 | 2004-06-03 | Nicholas Piramal India Limited | Improved process for preparation of gabapentin |
| DE60233355D1 (de) * | 2002-11-20 | 2009-09-24 | Hikal Ltd | Verbessertes verfahren zur zubereitung von gabalactam |
| WO2004052360A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
| KR20070091049A (ko) | 2002-12-13 | 2007-09-06 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
| AU2003283718A1 (en) * | 2002-12-13 | 2004-07-09 | Warner-Lambert Company Llc | Gabapentin analogues for fibromyalgia and other related disorders |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| RU2353358C2 (ru) * | 2002-12-13 | 2009-04-27 | Уорнер-Ламберт Компани Ллс | Производные прегабалина для лечения приливов |
| US20040180958A1 (en) * | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
| AU2003286300A1 (en) * | 2002-12-13 | 2004-07-09 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| GB0301143D0 (en) * | 2003-01-17 | 2003-02-19 | Amedis Pharm Ltd | Compounds and their use |
| PL377937A1 (pl) * | 2003-01-22 | 2006-02-20 | Warner-Lambert Company Llc | Pochodne cyklopropylo-beta-aminokwasu |
| MXPA05009504A (es) * | 2003-03-07 | 2005-10-18 | Warner Lambert Co | Derivados de (-aminoacidos sustituidos con tetrazol y oxadiazolona. |
| WO2004093827A2 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| DE602004017166D1 (de) * | 2003-03-25 | 2008-11-27 | Kiel Lab Inc | Gabapentintannat in flüssigen und/oder halbfesten dosierformen |
| WO2004093866A1 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Process for preparing phenolic acid salts of gabapentin |
| MXPA05010515A (es) * | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
| WO2004091278A2 (en) * | 2003-04-11 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Gabapentin compositions |
| ITMI20030825A1 (it) * | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione di gabapentin esente da |
| US7439387B2 (en) * | 2003-04-21 | 2008-10-21 | Matrix Laboratories Ltd. | Process for the preparation of Gabapentin form-II |
| CN1791430A (zh) * | 2003-05-16 | 2006-06-21 | 辉瑞产品公司 | 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合 |
| BRPI0411654A (pt) * | 2003-06-19 | 2006-08-08 | Pfizer Prod Inc | preparação biocatalìtica de ácido 1-cianocicloexanoacético |
| US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| EP1680125A1 (en) * | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| WO2005046566A2 (en) * | 2003-08-04 | 2005-05-26 | Sun Pharmaceutical Industries Limited | Stable gabapentin containing composition |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| EP1670451A4 (en) * | 2003-09-11 | 2009-10-21 | Xenoport Inc | TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS |
| AU2004271796A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders |
| RU2320369C2 (ru) * | 2003-09-12 | 2008-03-27 | Пфайзер Инк. | Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина |
| MXPA06003043A (es) * | 2003-09-17 | 2006-05-31 | Xenoport Inc | Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba. |
| KR101096480B1 (ko) | 2003-10-14 | 2011-12-20 | 제노포트 인코포레이티드 | 감마-아미노부티르산 유사체의 결정질 형태 |
| ITMI20032165A1 (it) * | 2003-11-11 | 2005-05-12 | Zambon Spa | Processo di preparazione di gabapentina |
| JP5646126B2 (ja) | 2003-12-11 | 2014-12-24 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法 |
| EP1737466A1 (en) * | 2004-01-29 | 2007-01-03 | Pfizer Products Inc. | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS |
| US20050187295A1 (en) * | 2004-02-19 | 2005-08-25 | Surendra Kalyan | Processes for the preparation of gabapentin |
| EP1763503A1 (en) * | 2004-03-17 | 2007-03-21 | Hikal Limited | 4-t-butylgabapentin and its synthesis |
| ITMI20040579A1 (it) * | 2004-03-25 | 2004-06-25 | Zambon Spa | Processo di preparazione di gabapentina |
| US20050233010A1 (en) * | 2004-04-19 | 2005-10-20 | Satow Philip M | Lithium combinations, and uses related thereto |
| AU2005256944A1 (en) * | 2004-06-09 | 2006-01-05 | Pfizer Inc. | Use of reboxetine for the treatment of pain |
| GB0416228D0 (en) * | 2004-07-20 | 2004-08-25 | Sandoz Ind Products S A | Process for the preparation of gabapentin |
| GB0419849D0 (en) * | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
| DE602005021907D1 (de) * | 2004-09-10 | 2010-07-29 | Newron Pharm Spa | Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal-selektive modulatoren |
| US8795725B2 (en) * | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| BRPI0616401A2 (pt) * | 2005-09-23 | 2011-06-21 | Janssen Pharmaceutica Nv | moduladores de hexa-hidro-ciclo-otil pirazol canabinoide e uso dos mesmos |
| EP1937646A1 (en) | 2005-09-23 | 2008-07-02 | Janssen Pharmaceutica N.V. | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| CA2623745A1 (en) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| EP1979593B1 (en) * | 2006-02-03 | 2017-12-06 | Rolls-Royce Corporation | Gas turbine engine fuel system with fuel metering valve |
| EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| US7795294B2 (en) * | 2006-02-14 | 2010-09-14 | Janssen Pharmaceutica N.V. | Tetrahydro-2H-indazole pyrazole cannabinoid modulators |
| KR20080100284A (ko) * | 2006-03-06 | 2008-11-14 | 화이자 프로덕츠 인코포레이티드 | 비-회복성 수면을 위한 알파-2-델타 리간드 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20070254911A1 (en) * | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
| WO2007112402A1 (en) * | 2006-03-27 | 2007-10-04 | Janssen Pharmaceutica N.V. | Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| US7442834B2 (en) * | 2006-06-12 | 2008-10-28 | Zhejiang Chiral Medicine Chemicals Co., Ltd. | Process suitable for industrial scale production of gabapentin |
| CA2660769C (en) * | 2006-06-30 | 2013-12-03 | Zach System S.P.A. | Process for preparing gabapentin |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080161393A1 (en) * | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
| EA017171B1 (ru) | 2006-12-22 | 2012-10-30 | Рекордати Айерленд Лимитед | КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП) |
| KR20090121388A (ko) * | 2007-03-15 | 2009-11-25 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 신규 전구약물 |
| WO2008157408A2 (en) * | 2007-06-15 | 2008-12-24 | Xenoport, Inc. | Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
| US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
| US20090062392A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched gabapentin |
| WO2009061934A1 (en) * | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| EP2250148B1 (en) * | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| CA2710538A1 (en) * | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| US20100190752A1 (en) * | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| EP2400989B1 (en) | 2009-02-24 | 2016-08-10 | Nektar Therapeutics | Gabapentin-peg conjugates |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2368872A1 (en) | 2010-03-25 | 2011-09-28 | Serichim S.r.l. | Process for the preparation of Gabapentin |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| WO2011151708A1 (en) | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
| US8431739B2 (en) | 2010-06-14 | 2013-04-30 | Divi's Laboratories, Ltd. | Process for the preparation of gabapentin |
| BR112013000164B1 (pt) | 2010-07-30 | 2021-11-23 | Toray Industries, Inc | Agente terapêutico ou agente profilático |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| JP2013216580A (ja) * | 2010-08-06 | 2013-10-24 | Kyorin Pharmaceutical Co Ltd | ビシクロ［２．２．２］オクチルアミン誘導体の製造方法 |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2530072A1 (en) | 2011-06-03 | 2012-12-05 | Lacer, S.A. | New compounds, synthesis and use thereof in the treatment of pain |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| ITMI20131757A1 (it) | 2013-10-22 | 2015-04-23 | Zach System Spa | Processo di preparazione di gabapentina |
| KR20160081864A (ko) | 2013-11-01 | 2016-07-08 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 티올기를 갖는 d-체 또는 l-체 아미노산 유도체의 제조 방법 |
| TW201607538A (zh) | 2013-12-17 | 2016-03-01 | 以斯提夫博士實驗室股份有限公司 | 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物 |
| JP2017503765A (ja) | 2013-12-17 | 2017-02-02 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | ガバペンチノイドおよびシグマ受容体の組み合わせ |
| EP2923694B1 (en) | 2014-03-27 | 2018-11-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral liquid pharmaceutical solution of gabapentin |
| MA49114A (fr) | 2016-12-16 | 2020-03-25 | Idorsia Pharmaceuticals Ltd | Combinaison pharmaceutique comprenant un bloqueur de canal calcique de type t |
| MX384760B (es) | 2018-07-04 | 2025-03-14 | Federico Amezcua Amezcua | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. |
| US10399926B1 (en) | 2018-08-01 | 2019-09-03 | Divi's Laboratories Ltd. | Process for the preparation of gabapentin |
| BR112021006004A2 (pt) | 2018-10-11 | 2021-06-29 | Sanifit Therapeutics S.A. | inositol fosfatos para o tratamento de calcificações ectópicas. |
| EP4049679A4 (en) | 2019-10-25 | 2023-11-01 | Kyoto University | Preventative or therapeutic agent for tauopathy |
| MX2022010960A (es) | 2020-03-04 | 2022-11-16 | Pleopharma L L C | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. |
| EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
| GB2625579A (en) | 2022-12-21 | 2024-06-26 | Novumgen Ltd | An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same |
-
1974
- 1974-12-21 DE DE2460891A patent/DE2460891C2/de not_active Expired
-
1975
- 1975-12-15 IE IE2736/75A patent/IE42382B1/en unknown
- 1975-12-15 GB GB5119375A patent/GB1465229A/en not_active Expired
- 1975-12-18 FR FR7538818A patent/FR2294697A1/fr active Granted
- 1975-12-18 CH CH430778A patent/CH612665A5/xx not_active IP Right Cessation
- 1975-12-18 CH CH430878A patent/CH612666A5/xx active Protection Beyond IP Right Term
- 1975-12-18 CH CH1645175A patent/CH612664A5/xx not_active IP Right Cessation
- 1975-12-18 BE BE6045299A patent/BE836835A/xx not_active IP Right Cessation
- 1975-12-19 SE SE7514442A patent/SE423385B/xx active Protection Beyond IP Right Term
- 1975-12-19 DK DK581475A patent/DK147706C/da not_active IP Right Cessation
- 1975-12-19 FI FI753613A patent/FI62282C/fi not_active IP Right Cessation
- 1975-12-19 LU LU74058A patent/LU74058A1/xx unknown
- 1975-12-19 CA CA242,147A patent/CA1052811A/en not_active Expired
- 1975-12-19 ES ES443723A patent/ES443723A1/es not_active Expired
- 1975-12-20 NL NLAANVRAGE7514900,A patent/NL181006C/xx not_active IP Right Cessation
- 1975-12-22 JP JP15319475A patent/JPS5324064B2/ja not_active Expired
- 1975-12-22 AT AT975075A patent/AT340892B/de active Protection Beyond IP Right Term
- 1975-12-31 US US05/645,724 patent/US4024175A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IE42382L (en) | 1976-06-21 |
| CH612666A5 (OSRAM) | 1979-08-15 |
| JPS5324064B2 (OSRAM) | 1978-07-18 |
| FR2294697B1 (OSRAM) | 1978-07-28 |
| SE423385B (sv) | 1982-05-03 |
| FR2294697A1 (fr) | 1976-07-16 |
| DK147706B (da) | 1984-11-19 |
| CA1052811A (en) | 1979-04-17 |
| US4024175A (en) | 1977-05-17 |
| FI62282B (fi) | 1982-08-31 |
| CH612665A5 (OSRAM) | 1979-08-15 |
| IE42382B1 (en) | 1980-07-30 |
| CH612664A5 (OSRAM) | 1979-08-15 |
| LU74058A1 (OSRAM) | 1976-07-20 |
| SE7514442L (sv) | 1976-06-22 |
| NL7514900A (nl) | 1976-06-23 |
| ATA975075A (de) | 1977-05-15 |
| DK581475A (da) | 1976-01-22 |
| GB1465229A (en) | 1977-02-23 |
| DE2460891C2 (de) | 1982-09-23 |
| AT340892B (de) | 1978-01-10 |
| BE836835A (fr) | 1976-06-18 |
| JPS5188940A (OSRAM) | 1976-08-04 |
| NL181006C (nl) | 1987-06-01 |
| NL181006B (nl) | 1987-01-02 |
| FI753613A7 (OSRAM) | 1976-06-22 |
| DE2460891A1 (de) | 1976-07-01 |
| DK147706C (da) | 1985-05-13 |
| AU8774175A (en) | 1977-06-23 |
| ES443723A1 (es) | 1977-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI62282C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror | |
| US4087544A (en) | Treatment of cranial dysfunctions using novel cyclic amino acids | |
| AU734173B2 (en) | Novel substituted cyclic amino acids as pharmaceutical agents | |
| CH631696A5 (de) | Verfahren zur herstellung von olefinischen derivaten von aminosaeuren. | |
| NO142172B (no) | Analogifremgangsmaate for fremstilling av som antikonvulsiva virksomme alfa-fenyl-benzyliden-aminosyrederivater | |
| PT820438E (pt) | O-carbamoil-fenilalaninol possuindo um substituinte no anel benzeno, seus sais farmaceuticamente uteis e processo para preparacao do mesmo | |
| CA1080715A (en) | Acetylene derivatives of amino acids | |
| KR0152069B1 (ko) | 알파,알파-이치환 n-시클로알킬 알킬 벤질아민, 이들의 제조방법, 의약품으로서 이들의 용도 및 이들의 합성 중간체 | |
| NO156608B (no) | Analogifremgangsmaate for fremstiling av terapeutisk aktive amider av 4-aminosmoersyre. | |
| EP0136274B1 (en) | 1-piperazine carboxamide derivatives, their preparation and their use in pharmaceutical compositions | |
| Laursen et al. | Formal total synthesis of the PKC inhibitor, balanol: preparation of the fully protected benzophenone fragment | |
| DK149269B (da) | Analogifremgangsmaade til fremstilling af beta-mono- eller -difluormethyl-beta-alanin-derivater eller farmaceutisk acceptable salte eller optiske isomere deraf | |
| CA2712858A1 (en) | Novel process for the preparation of vorinostat | |
| Chatterjie et al. | Synthesis of valproic acid amides of a melatonin derivative, a piracetam and amantadine for biological tests | |
| EP0543343A2 (de) | Verfahren zur Herstellung von alpha-Hydroxy-beta-aminocarbonsäuren | |
| Leonard et al. | Centrally Active 2-(Substituted phenyl)-β-alanines1 | |
| US4041041A (en) | Acetylene derivatives of amino acids | |
| US4418077A (en) | Fluorinated amino-butyric acid and diaminobutane derivatives | |
| Portoghese | Stereochemical studies on medicinal agents. II. absolute configuration of (-)-phenampromide | |
| US4353923A (en) | Pharmaceutical composition containing a benzofurancarboxamide derivative as the active ingredient | |
| US4435425A (en) | Fluorinated diaminobutane derivatives | |
| EP0046712B1 (en) | Fluorinated diaminobutane derivatives | |
| US3374265A (en) | Diphenyl hydroxy carbamate compounds | |
| US4039549A (en) | Olefinic derivatives of amino acids | |
| USRE31980E (en) | Olefinic derivatives of amino acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired | ||
| ND | Supplementary protection certificate (spc) granted | ||
| SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L56 Extension date: 20001219 |
|
| MA | Patent expired |
Owner name: WARNER-LAMBERT COMPANY |